<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929031</url>
  </required_header>
  <id_info>
    <org_study_id>1335.1</org_study_id>
    <nct_id>NCT01929031</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain</brief_title>
  <official_title>A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of a combination product
      containing ibuprofen 400 mg and caffeine 100 mg versus either ingredient alone as well as
      placebo for the treatment of post-surgical dental pain over an eight-hour period followed by
      a single dose of study medication (study stage 1). A secondary objective is to evaluate
      efficacy of multiple doses of the combination in comparison to ibuprofen alone over a 5-day
      post-surgical period (study stage 2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)</measure>
    <time_frame>0 to 8 hours</time_frame>
    <description>SPRID0-8h: Time-weighted sum of PAR and PID from 0 to 8 hours, score range: -40 (worst) to 112 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5,2,3,4,5, 6,7 and 8 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 8 were considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 8 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)</measure>
    <time_frame>0 to 2 hours</time_frame>
    <description>SPRID0-2h: Time-weighted sum of PAR and PID from 0 to 2 hours, score range: -10 (worst) to 28 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5 and 2 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 2 was considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 2 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Pain Relief</measure>
    <time_frame>8 hours</time_frame>
    <description>Duration of pain relief was defined as the time between the administration of first dose of trial medication and first dose of rescue medication or second dose of trial medication, whichever was first. Duration of pain relief was censored at 8 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Meaningful Pain Relief</measure>
    <time_frame>8 hours</time_frame>
    <description>Time to meaningful pain relief was captured by a stopwatch, which was started by the study staff immediately after the administration of the first dose of trial medication and which was to be stopped by the patient as soon as he/she felt meaningful pain relief. Time to meaningful pain relief was censored at 8 hours.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">562</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Tooth Diseases</condition>
  <arm_group>
    <arm_group_label>Caffeine-Ibuprofen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Ibuprofen/Caffeine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen/Caffeine-Ibuprofen/Caffeine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen-Ibuprofen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine-Ibuprofen/Caffeine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Ibuprofen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen + caffeine</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>Placebo-Ibuprofen/Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
    <description>tablet.</description>
    <arm_group_label>Ibuprofen-Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
    <description>tablet</description>
    <arm_group_label>Caffeine-Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>tablet</description>
    <arm_group_label>Caffeine-Ibuprofen/Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen + caffeine</intervention_name>
    <description>Fixed Dose Combination (FDC) tablet</description>
    <arm_group_label>Ibuprofen/Caffeine-Ibuprofen/Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo-Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo-Ibuprofen/Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>tablet</description>
    <arm_group_label>Caffeine-Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo-Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen + caffeine</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>Caffeine-Ibuprofen/Caffeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Males and females 18 to 55 years of age;

          -  Outpatients scheduled to undergo surgical extraction of 3-4 impacted third molar(s),
             with a minimum of two mandibular extractions. The two mandibular third molars may be
             partial bony impactions or full bony impactions (as long as the trauma rating is not
             severe and the surgeons do not feel the subject will have extreme post-surgical pain)
             OR there may be a combination of one full bony impaction with the second mandibular
             being a soft tissue impaction or partial bony impaction. Maxillary third molars (or
             supernumerary teeth) of any type can be extracted;

          -  Use of only the following preoperative medication(s)/ anesthetic(s): topical
             benzocaine, short-acting local anesthetic (mepivacaine or lidocaine) with or without
             vasoconstrictor and/or nitrous oxide;

          -  Reliable, cooperative, and of adequate intelligence to record the requested
             information on the analgesic questionnaire form;

          -  Examined by the attending oral surgeon or physician and medically cleared to
             participate in the study;

          -  Scheduled to undergo a qualifying surgical procedure;

          -  In good general health, with a BMI of 30 or less, and have no contraindications to any
             of the study medications or anesthetic drugs;

          -  Subjects have at least a categorical pain score of moderate and a numerical rating
             scale (NRS) score of 5 or greater within 4.5 hours from the time of the last suture.

        Exclusion criteria:

          -  Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly
             controlled diabetes, significantly impaired cardiac, renal or hepatic function, hyper-
             or hypothyroidism);

          -  Use of a prescription or non-prescription drug with which the administration of
             ibuprofen or any other non steroidal anti inflammatory or caffeine is contraindicated;

          -  Acute local infection at the time of surgery that could confound the post-surgical
             evaluation;

          -  Females who are pregnant, lactating, of child-bearing potential, or post-menopausal
             for less than 2 years and not using a medically approved method of contraception
             (i.e., oral, transdermal, intravaginal or implanted contraceptives, intrauterine
             device, diaphragm, condom, abstinence, or surgical sterility), or females who test
             positive on a urine-based pregnancy test;

          -  Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic
             ulcer disease;

          -  History of alcoholism or substance abuse within the last year, or is currently abusing
             alcohol or other mood-altering drugs (e.g., cannabis). Subjects who are taking central
             nervous system or other psychotropic drugs (including St. Johns Wort, or any other
             nutritional supplement known to have psychotropic effects) may be enrolled if they
             have been on stable doses of medication for at least 2 months, will maintain this dose
             throughout the study, and their condition is judged by the Principal Investigator to
             be well-controlled;

          -  Habituation to analgesic drugs or caffeine (i.e., routine use of oral analgesics 5 or
             more times per week or ingestion of 4 or more caffeine-containing drinks daily); use
             of &quot;high energy&quot; drinks more than once per week;

          -  Use of any type of systemic corticosteroid within the past 30 days or a history of
             current or previous use of anabolic steroids;

          -  History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to
             acetaminophen, ibuprofen, naproxen, aspirin, celecoxib, or any other non steroidal
             anti inflammatory or caffeine;

          -  Prior use of any type of analgesic or non steroidal anti inflammatory within 5
             half-lives of that drug before surgery, except for pre-anesthetic medication and
             anesthesia for the procedure;

          -  Ingestion of any caffeine-containing beverages, chocolate, or alcohol 6 hours or less
             before surgery;

          -  Has impaired liver function, e.g., serum Alanine transaminase, aspartate
             aminotransferase, alkaline phosphatase, or Gamma-glutamyltransferase greater than 2.5
             times the upper limit of normal, or blood urea nitrogen, creatinine, or bilirubin
             greater than 1.5 times the upper limit of normal without a known benign explanation;

          -  Has known history of a positive HIV antibody test or known HIV infection;

          -  Has a known history of Hepatitis B or C;

          -  Has a clinically significant abnormal electrocardiogram (ECG) at screening as
             determined by the Investigator:

          -  Has taken an investigational product within the past 30 days;

          -  Has previously been entered into this study;

          -  The subject is a member of the study site staff either directly involved with the
             study, an employee of the Sponsor, or a relative of study site personnel directly
             involved with the study or Sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1335.1.202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <results_first_submitted>February 18, 2015</results_first_submitted>
  <results_first_submitted_qc>September 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2016</results_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Toothache</mesh_term>
    <mesh_term>Tooth Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ibuprofen/Caffeine - Ibuprofen/Caffeine</title>
          <description>Study stage 1: One Ibuprofen 400mg/Caffeine 100mg tablet after dental surgery; Study stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen400mg/Caffeine 100mg tablet, while awake, over 5 days</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen - Ibuprofen</title>
          <description>Study stage 1: One Ibuprofen 400mg tablet after dental surgery; Study stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400mg tablet, while awake, over 5 days</description>
        </group>
        <group group_id="P3">
          <title>Caffeine - Ibuprofen/Caffeine</title>
          <description>Study stage 1: One Caffeine 100mg tablet after dental surgery; Study stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100mg tablet, while awake, over 5 days</description>
        </group>
        <group group_id="P4">
          <title>Caffeine - Ibuprofen</title>
          <description>Study stage 1: One Caffeine 100mg tablet after dental surgery; Study stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400mg tablet, while awake, over 5 days</description>
        </group>
        <group group_id="P5">
          <title>Placebo - Ibuprofen/Caffeine</title>
          <description>Study stage 1: One Placebo tablet after dental surgery; Study stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100mg tablet, while awake, over 5 days</description>
        </group>
        <group group_id="P6">
          <title>Placebo - Ibuprofen</title>
          <description>Study stage 1: One Placebo tablet after dental surgery; Study stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400mg tablet, while awake, over 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated patients</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Stage 1</title>
          <description>One Placebo tablet after dental surgery</description>
        </group>
        <group group_id="B2">
          <title>Caffeine Stage 1</title>
          <description>One Caffeine 100mg tablet after dental surgery</description>
        </group>
        <group group_id="B3">
          <title>Ibuprofen Stage 1</title>
          <description>One Ibuprofen 400mg tablet after dental surgery</description>
        </group>
        <group group_id="B4">
          <title>Ibuprofen/Caffeine Stage 1</title>
          <description>One Ibuprofen 400mg/Caffeine 100mg tablet after dental surgery</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="209"/>
            <count group_id="B4" value="213"/>
            <count group_id="B5" value="562"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" spread="1.77"/>
                    <measurement group_id="B2" value="19.2" spread="1.72"/>
                    <measurement group_id="B3" value="19.6" spread="1.96"/>
                    <measurement group_id="B4" value="19.5" spread="2.06"/>
                    <measurement group_id="B5" value="19.5" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="213"/>
                    <measurement group_id="B5" value="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)</title>
        <description>SPRID0-8h: Time-weighted sum of PAR and PID from 0 to 8 hours, score range: -40 (worst) to 112 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5,2,3,4,5, 6,7 and 8 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 8 were considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 8 hours.</description>
        <time_frame>0 to 8 hours</time_frame>
        <population>Randomized patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet after dental surgery</description>
          </group>
          <group group_id="O2">
            <title>Caffeine</title>
            <description>One Caffeine 100mg tablet after dental surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen</title>
            <description>One Ibuprofen 400mg tablet after dental surgery</description>
          </group>
          <group group_id="O4">
            <title>Ibuprofen/Caffeine</title>
            <description>One Ibuprofen 400mg/Caffeine 100mg tablet after dental surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)</title>
          <description>SPRID0-8h: Time-weighted sum of PAR and PID from 0 to 8 hours, score range: -40 (worst) to 112 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5,2,3,4,5, 6,7 and 8 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 8 were considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 8 hours.</description>
          <population>Randomized patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.554" spread="3.527"/>
                    <measurement group_id="O2" value="15.824" spread="3.525"/>
                    <measurement group_id="O3" value="40.165" spread="2.047"/>
                    <measurement group_id="O4" value="52.291" spread="2.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The statistical model included baseline PI (VRS), and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>41.738</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.058</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.767</ci_lower_limit>
            <ci_upper_limit>49.708</ci_upper_limit>
            <estimate_desc>Ibuprofen/Caffeine vs. Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The statistical model included baseline PI (VRS), and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>36.467</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.058</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.497</ci_lower_limit>
            <ci_upper_limit>44.437</ci_upper_limit>
            <estimate_desc>Ibuprofen/Caffeine vs. Caffeine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The statistical model included baseline PI (VRS), and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.868</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.493</ci_lower_limit>
            <ci_upper_limit>17.759</ci_upper_limit>
            <estimate_desc>Ibuprofen/Caffeine vs. Ibuprofen</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)</title>
        <description>SPRID0-2h: Time-weighted sum of PAR and PID from 0 to 2 hours, score range: -10 (worst) to 28 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5 and 2 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 2 was considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 2 hours.</description>
        <time_frame>0 to 2 hours</time_frame>
        <population>Patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet after dental surgery</description>
          </group>
          <group group_id="O2">
            <title>Caffeine</title>
            <description>One Caffeine 100mg tablet after dental surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen</title>
            <description>One Ibuprofen 400mg tablet after dental surgery</description>
          </group>
          <group group_id="O4">
            <title>Ibuprofen/Caffeine</title>
            <description>One Ibuprofen 400mg/Caffeine 100mg tablet after dental surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 2 Hours (SPRID0-2h)</title>
          <description>SPRID0-2h: Time-weighted sum of PAR and PID from 0 to 2 hours, score range: -10 (worst) to 28 (best). PI was assessed on a 0-10 numerical pain rating scale (NPRS), where 0=no pain and 10=worst possible pain, pre-dose and at 0.25,0.5,0.75,1,1.5 and 2 hours; PAR was assessed on a 5-point verbal rating scale (VRS) (0=none to 4=complete) at the same post-dose time points. Time-weights were equal to the elapsed time (hour) between the time point of interest and the preceding time point. All PAR and pain intensity (PI) assessments completed after the patient had taken rescue medication or the second dose of study medication, whichever was first, until hour 2 was considered missing. Last observation carried forward (LOCF) was used with the last completed PI/PAR assessments prior to first rescue/second study medication, whichever was first, to impute missing values up to 2 hours.</description>
          <population>Patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.059" spread="0.703"/>
                    <measurement group_id="O2" value="2.612" spread="0.702"/>
                    <measurement group_id="O3" value="6.990" spread="0.408"/>
                    <measurement group_id="O4" value="10.584" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The statistical model included baseline PI (VRS), and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.525</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.808</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.937</ci_lower_limit>
            <ci_upper_limit>10.113</ci_upper_limit>
            <estimate_desc>Ibuprofen/Caffeine vs. Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The statistical model included baseline PI (VRS), and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.972</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.808</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.384</ci_lower_limit>
            <ci_upper_limit>9.559</ci_upper_limit>
            <estimate_desc>Ibuprofen/Caffeine vs. Caffeine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The statistical model included baseline PI (VRS), and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.594</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.571</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.472</ci_lower_limit>
            <ci_upper_limit>4.716</ci_upper_limit>
            <estimate_desc>Ibuprofen/Caffeine vs. Ibuprofen</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Pain Relief</title>
        <description>Duration of pain relief was defined as the time between the administration of first dose of trial medication and first dose of rescue medication or second dose of trial medication, whichever was first. Duration of pain relief was censored at 8 hours.</description>
        <time_frame>8 hours</time_frame>
        <population>Patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet after dental surgery</description>
          </group>
          <group group_id="O2">
            <title>Caffeine</title>
            <description>One Caffeine 100mg tablet after dental surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen</title>
            <description>One Ibuprofen 400mg tablet after dental surgery</description>
          </group>
          <group group_id="O4">
            <title>Ibuprofen/Caffeine</title>
            <description>One Ibuprofen 400mg/Caffeine 100mg tablet after dental surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Pain Relief</title>
          <description>Duration of pain relief was defined as the time between the administration of first dose of trial medication and first dose of rescue medication or second dose of trial medication, whichever was first. Duration of pain relief was censored at 8 hours.</description>
          <population>Patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" lower_limit="1.60" upper_limit="2.07"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.67" upper_limit="3.83"/>
                    <measurement group_id="O3" value="7.11" lower_limit="6.43" upper_limit="7.77"/>
                    <measurement group_id="O4" value="7.33" lower_limit="7.05" upper_limit="7.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen/Caffeine vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen/Caffeine vs. Caffeine</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen/Caffeine vs. Ibuprofen</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2389</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Meaningful Pain Relief</title>
        <description>Time to meaningful pain relief was captured by a stopwatch, which was started by the study staff immediately after the administration of the first dose of trial medication and which was to be stopped by the patient as soon as he/she felt meaningful pain relief. Time to meaningful pain relief was censored at 8 hours.</description>
        <time_frame>8 hours</time_frame>
        <population>Patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One Placebo tablet after dental surgery</description>
          </group>
          <group group_id="O2">
            <title>Caffeine</title>
            <description>One Caffeine 100mg tablet after dental surgery</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen</title>
            <description>One Ibuprofen 400mg tablet after dental surgery</description>
          </group>
          <group group_id="O4">
            <title>Ibuprofen/Caffeine</title>
            <description>One Ibuprofen 400mg/Caffeine 100mg tablet after dental surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meaningful Pain Relief</title>
          <description>Time to meaningful pain relief was captured by a stopwatch, which was started by the study staff immediately after the administration of the first dose of trial medication and which was to be stopped by the patient as soon as he/she felt meaningful pain relief. Time to meaningful pain relief was censored at 8 hours.</description>
          <population>Patients who used at least one dose of study medication and provided any post-treatment data for the primary efficacy endpoint (FAS)</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">because more than half of the patients were without meaningful pain relief within 8 h</measurement>
                    <measurement group_id="O2" value="NA">because more than half of the patients were without meaningful pain relief within 8 h</measurement>
                    <measurement group_id="O3" value="1.78" lower_limit="1.48" upper_limit="2.02"/>
                    <measurement group_id="O4" value="1.13" lower_limit="0.93" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen/Caffeine vs. Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen/Caffeine vs. Caffeine</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen/Caffeine vs. Ibuprofen</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified for baseline pain intensity as measured on the 4-point VRS.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug date/time until drug discontinuation date + 24 hours (inclusive)</time_frame>
      <desc>Patients at risk and reported adverse events were allocated to the actual treatment patients were exposed to, regardless of the study stage.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
        <group group_id="E2">
          <title>Caffeine</title>
          <description>Caffeine 100mg tablet</description>
        </group>
        <group group_id="E3">
          <title>Ibuprofen</title>
          <description>Ibuprofen 400mg tablet</description>
        </group>
        <group group_id="E4">
          <title>Ibuprofen/Caffeine</title>
          <description>Ibuprofen 400mg / Caffeine 100mg tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BIs intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

